NEW YORK--(BUSINESS WIRE)--Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced that its industry-leading technology platform has been adopted by China-based Shanghai Henlius Biotechnology Co. Ltd (“Henlius”). Focused on monoclonal antibody drug development, Henlius is utilizing the Medidata Clinical Cloud® platform to bring operational efficiencies to its complex Phase III oncology clinical trial in China.

“To meet the specific and intricate requirements of our oncology study, as well as continue driving innovation for the patients we serve, it’s imperative that we combine our therapeutic expertise with the industry’s most cutting-edge technology,” said Dr. Yin Liu, director of Henlius’ clinical and medical department. “Medidata’s unified, robust technology platform provides our team with real-time visibility into clinical data and trial operations. This visibility enables better trial oversight and opportunities to make earlier, more informed decisions.”

A joint venture between Shanghai Fosun Pharmaceutical, one of the largest pharma companies in China, and Henlius Biopharmaceuticals, a top Chinese biotechnology company, Shanghai Henlius Biotech was founded in 2009. The organization focuses on the development, production and commercialization of monoclonal antibody drugs for a number of therapeutic areas, including oncology and auto-immune diseases. To optimize trial operations and streamline process workflows in an upcoming Phase III oncology study, Henlius is using Medidata’s unified cloud-based solution for electronic data capture (Medidata Rave®) and randomization and trial supply management (Medidata Balance®).
“By offering a single, integrated system for capturing clinical data, randomizing patients and dispensing treatment doses, Medidata’s cloud-based platform is enabling Henlius to streamline study operations and easily make mid-study supply adjustments—reducing costs, trial risk and overall timelines,” said Edwin Ng, Medidata’s vice president of field operations, APeJ (Asia Pacific except Japan). “We look forward to enriching Henlius’ deep therapeutic expertise with our robust technology, helping its research team conduct faster, more efficient and more meaningful trials that ultimately result in more effective treatments for patients.”

Connect with Medidata:

Read our blog, Geeks Talk Clinical
Tweet this: #Chinese #biotech Henlius leverages @Medidata #tech to optimize its #oncology #clinicalresearch http://ow.ly/ZR4Qm #data #randomization

Medical Research Homepage